Antiangiogenic antithrombin

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 660-666

  O'Reilly, Michael S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Antithrombin; Malignancy; Metastasis; Small cell lung cancer

Indexed keywords

ANTITHROMBIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; ENDOTHELIUM CELL; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTITHROMBINS; CARCINOMA, SMALL CELL; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN CONFORMATION;

EID: 36349030324     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991533     Document Type: Review

References (74)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
2. Fidler IJ, Kerbel RS, Ellis LM. Biology of cancer: angiogenesis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:137-147
3. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986;315:1650-1659
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
6. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-6628
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364
8. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005;102:2934-2939
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
10. Miller KD, Sledge GW Jr, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007;5:1-12
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
12. Beerepoot LV, Witteveen EO, Groenewegen G, et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 2003;9:4025-4033
13. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-3803
14. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-3561
15. Kurup A, Lin CW, Murry DJ, et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17:97-103
16. O'Reilly MS, Fidler IJ. The development of antiangiogenic agents for the clinic. In: DeVita VT, Hellman S, Rosenberg SA, eds. Progress in Oncology 2002. Sudbury, MA: Jones and Bartlett; 2002:129-157
17. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-2211
18. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 1983;39:71-120
19. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328
20. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2-4
21. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285
22. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-1928
23. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810
24. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-29571
25. Evans DL, Marshall CJ, Christey PB, Carrell RW. Heparin binding site, conformational change, and activation of antithrombin. Biochemistry 1992;31:12629-12642
26. Mourey L, Samama J, Delarue M, et al. Crystal structure of cleaved bovine antithrombin III at 3.2 angstrom resolution. J Mol Biol 1993;232:223-241
27. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301:1179-1190
28. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-2356
29. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-1215
30. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-21348
31. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-2526
32. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA 2001;98:620-624
33. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-1299
34. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129:896-900
35. Ge G, Fernandez CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 2007;104:10010-10015
36. Jiang WG, Hiscox SE, Parr C, et al. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 1999;5:3695-3703
37. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000;95:543-550
38. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-79
39. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511
40. Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006;12:7444-7455
41. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995;92:7799-7803
42. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991;9:543-551
43. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-1241
44. Mourey L, Samama JP, Delarue M, et al. Antithrombin III: structural and functional aspects. Biochimie 1990;72:599-608
45. Pratt CW, Church FC. Antithrombin: structure and function. Semin Hematol 1991;28:3-9
46. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991;353:576-578
47. Huntington JA, Gettins PGW. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin. Biochemistry 1998;37:3272-3277
48. Schreuder HA, de Boer B, Dijkema R, et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol 1994;1:48-54
49. Wardell MR, Chang WW, Bruce D, et al. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 1997;36:13133-13142
50. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001;61:7298-7304
51. Prox D, Becker C, Pirie-Shepherd SR, et al. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003;27:405-411
52. Larsson H, Sjoblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000;60:6723-6729
53. Larsson H, Akerud P, Nordling K, et al. A novel antiangiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 2001;276:11996-12002
54. Caunt M, Hu L, Tang T, et al. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006;66:4125-4132
55. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-668
56. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001;86:1094-1098
57. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969-23976
58. Lockwood CJ, Toti P, Arcuri F, et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol 2007;170:1398-1405
59. Zhang W, Chuang YJ, Jin T, et al. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006;66:5047-5055
60. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378
61. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science 1989;243:1490-1493
62. Zhang W, Chuang YJ, Swanson R, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004;103:1185-1191
63. Zhang W, Swanson R, Xiong Y, Richard B, Olson ST. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J Biol Chem 2006;281:37302-37310
64. Yi M, Sakai T, Fassler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA 2003;100:11435-11438
65. Zacharski LR. Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. Onkologie 1987;10:264-270
66. Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer 1987;60:2675-2681
67. Akiyama K, Nakamura K, Makino I, et al. Antithrombin III producing hepatocellular carcinoma. Thromb Res 1993;72:193-201
68. Cao Y, Lundwall A, Gadaleanu V, Lilja H, Bjartell A. Antithrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate- specific antigen and human glandular kallikrein 2. Am J Pathol 2002;161:2053-2063
69. Laschke MW, Cengiz Z, Hoffmann JN, Menger MD, Vollmar B. Latent antithrombin does not affect physiological angiogenesis: an in vivo study on vascularization of grafted ovarian follicles. Life Sci 2004;75:203-213
70. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275:1521-1524
71. O'Reilly MS. Antiangiogenesis: basic principles. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:827-843
72. Camphausen K, Purow B, Sproull M, et al. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci USA 2005;102:8287-8292
73. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007;101:927-936
74. Nakamura T, Fidler IJ, Coombes KR. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res 2007;67:139-148